Drawing for BRYVORA

USPTO serial 88077665

BRYVORA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SIRIGNANO, EMMA MARIE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BRYVORA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III TEPPER & EYSTER, PLLC3724 BENSON DRIVERALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; all of the foregoing excluding pharmaceutical preparations for the treatment of genetic diseases and disorders and pharmaceutical preparations for use in enzyme therapyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Aug 15, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 15, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 15, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 14, 2022EX5GSOU EXTENSION 5 GRANTED—
Jan 14, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 6, 2022EXT5SOU EXTENSION 5 FILED—
Jan 6, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 3, 2022DOCKASSIGNED TO EXAMINER—
Jul 7, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 5, 2021EX4GSOU EXTENSION 4 GRANTED—
Jul 5, 2021EXT4SOU EXTENSION 4 FILED—
Jul 5, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 7, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 5, 2021EX3GSOU EXTENSION 3 GRANTED—
Jan 5, 2021EXT3SOU EXTENSION 3 FILED—
Jan 5, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 7, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 3, 2020EX2GSOU EXTENSION 2 GRANTED—
Jul 3, 2020EXT2SOU EXTENSION 2 FILED—
Jul 3, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 9, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 7, 2020EX1GSOU EXTENSION 1 GRANTED—
Jan 7, 2020EXT1SOU EXTENSION 1 FILED—
Jan 7, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 9, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 30, 2019CHPBPOST PUBLICATION AMENDMENT - ENTERED—
May 28, 2019APETASSIGNED TO PETITION STAFF—
May 23, 2019ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
May 2, 2019EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Dec 12, 2018ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Nov 13, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 13, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 24, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 28, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 20, 2018DOCKASSIGNED TO EXAMINER—
Aug 22, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 17, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance